Search - tctmd.com

Displaying 21 - 40 of 47

Sort: Relevancy | Date

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Daily News

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Michael O'Riordan

January 25, 2021

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Diabetes Does Not Appear to Hinder FFR Insights for CAD

Caitlin E. Cox

January 09, 2020

News Daily News

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Yael L. Maxwell

October 10, 2019

News Daily News

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Michael O'Riordan

November 23, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Daily News

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

L.A. McKeown

January 30, 2017

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

Advertisement

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

A Simple Nudge Moves the Needle on Statin Prescribing

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Diabetes Does Not Appear to Hinder FFR Insights for CAD

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content